Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

• Status: Not yet recruiting
• Trial end date: 2026-10-01

Summary

This phase I/II trial tests the safety and efficacy of split-course, adaptive radiation therapy in combination with pembrolizumab with or without chemotherapy for the treatment of patients with stage IV lung cancer who have a limited number of metastases. Radiation therapy is a standard cancer treatment that uses highly focused, high energy x-rays to kill cancer cells and shrink tumors. In this trial, radiation therapy will be given as a split-course, with each treatment coinciding with the initiation of a cycle of standard of care immunotherapy. The radiation therapy is adaptive and individualized, meaning that its intensity and shape will be tailored to a patient's disease response while on treatment. Immunotherapy with monoclonal antibodies such as pembrolizumab may enhance how the body's immune system attacks cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs like carboplatin, pemetrexed, and nab-paclitaxel work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving split-course adaptive radiation therapy with standard treatments like immunotherapy and chemotherapy may be more effective at treating stage IV lung cancer than giving them alone.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Vanderbilt-Ingram Cancer Center
• Collaborators: National Cancer Institute (NCI); Varian Medical Systems
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Deoxyglucose; Fluorodeoxyglucose F18; Paclitaxel; Pembrolizumab; Pemetrexed